寶光股份(600379.SH):直接控股股東由寶光集團變更爲西電集團
格隆匯7月9日丨寶光股份(600379.SH)公佈,2025年7月9日,公司收到西電集團《關於無償劃轉股份完成過戶登記的告知函》及其提供的《上海證券交易所上市公司股份協議轉讓確認表》《中國證券登記結算有限公司證券過戶登記確認書》,獲悉本次國有股份無償劃轉涉及的股份已辦理完成過戶登記手續,本次國有股份無償劃轉涉及履行的程序已全部履行完畢。
本次國有股份無償劃轉過戶登記手續完成後,西電集團直接持有公司99,060,484股無限售流通股股份,佔公司總股本的30.00%,寶光集團不再持有公司股份。公司的直接控股股東由寶光集團變更爲西電集團,公司實際控制人未發生變化,仍爲國務院國資委。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.